An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

NCT ID: NCT00229658

Last Updated: 2015-03-25

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1297 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-09-30

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Type 1

Patients with type 1 diabetes

pramlintide acetate

Intervention Type DRUG

Subcutaneous injection prior to each major meal

Type 2

Patients with type 2 diabetes

pramlintide acetate

Intervention Type DRUG

Subcutaneous injection prior to each major meal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pramlintide acetate

Subcutaneous injection prior to each major meal

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Symlin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have failed to achieve the desired or optimal level of glycemic control despite utilizing appropriate, individualized insulin regimens
* Have A1C \<=9.0% within 3 months of study enrollment
* Are receiving ongoing diabetes care under the guidance of a Health Care Provider (HCP) trained in the use of SYMLIN

Exclusion Criteria

* Are poorly compliant with their current insulin regimen, as defined by their HCP
* Are poorly compliant with prescribed blood glucose self monitoring, as defined by their HCP
* Have experienced recurrent patient-ascertained severe hypoglycemia requiring assistance during the past 6 months
* Have hypoglycemia unawareness
* Have a confirmed diagnosis of gastroparesis
* Require the use of drugs that stimulate gastrointestinal motility
* Are female and pregnant or lactating and for whom the HCP determines the potential benefit does not justify the potential risk to the fetus or infant
* Have been treated with SYMLIN within 3 months prior to study start
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vice President, Medical Development, MD

Role: STUDY_DIRECTOR

Amylin Pharmaceuticals, LLC.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Birmingham, Alabama, United States

Site Status

Research Site

Montgomery, Alabama, United States

Site Status

Research Site

Tucson, Arizona, United States

Site Status

Research Site

Anaheim, California, United States

Site Status

Research Site

Encinitas, California, United States

Site Status

Research Site

Escondido, California, United States

Site Status

Research Site

Fresno, California, United States

Site Status

Research Site

Lafayette, California, United States

Site Status

Research Site

Moreno Valley, California, United States

Site Status

Research Site

Sacramento, California, United States

Site Status

Research Site

Salinas, California, United States

Site Status

Research Site

Santa Barbara, California, United States

Site Status

Research Site

Torrance, California, United States

Site Status

Research Site

Vacaville, California, United States

Site Status

Research Site

Arvada, Colorado, United States

Site Status

Research Site

Aurora, Colorado, United States

Site Status

Research Site

Norwalk, Connecticut, United States

Site Status

Research Site

Wilmington, Delaware, United States

Site Status

Research Site

Hialeah, Florida, United States

Site Status

Research Site

Jacksonville, Florida, United States

Site Status

Research Site

Maitland, Florida, United States

Site Status

Research Site

Melbourne, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Plantation, Florida, United States

Site Status

Research Site

Tallahassee, Florida, United States

Site Status

Research Site

Winter Haven, Florida, United States

Site Status

Research Site

Canton, Georgia, United States

Site Status

Research Site

Columbus, Georgia, United States

Site Status

Research Site

Roswell, Georgia, United States

Site Status

Research Site

Valdosta, Georgia, United States

Site Status

Research Site

‘Aiea, Hawaii, United States

Site Status

Research Site

Caldwell, Idaho, United States

Site Status

Research Site

Idaho Falls, Idaho, United States

Site Status

Research Site

Pocatello, Idaho, United States

Site Status

Research Site

Evergreen Park, Illinois, United States

Site Status

Research Site

Wheaton, Illinois, United States

Site Status

Research Site

Fort Wayne, Indiana, United States

Site Status

Research Site

Franklin, Indiana, United States

Site Status

Research Site

Indianapolis, Indiana, United States

Site Status

Research Site

Des Moines, Iowa, United States

Site Status

Research Site

Shawnee Mission, Kansas, United States

Site Status

Research Site

Wichita, Kansas, United States

Site Status

Research Site

Louisville, Kentucky, United States

Site Status

Research Site

Baton Rouge, Louisiana, United States

Site Status

Research Site

Lafayette, Louisiana, United States

Site Status

Research Site

Laplace, Louisiana, United States

Site Status

Research Site

Glen Burnie, Maryland, United States

Site Status

Research Site

Towson, Maryland, United States

Site Status

Research Site

Ann Arbor, Michigan, United States

Site Status

Research Site

Bloomfield, Michigan, United States

Site Status

Research Site

Detroit, Michigan, United States

Site Status

Research Site

Grand Rapids, Michigan, United States

Site Status

Research Site

Duluth, Minnesota, United States

Site Status

Research Site

Eagan, Minnesota, United States

Site Status

Research Site

Butte, Montana, United States

Site Status

Research Site

Las Vegas, Nevada, United States

Site Status

Research Site

Reno, Nevada, United States

Site Status

Research Site

Hamilton, New Jersey, United States

Site Status

Research Site

Jersey City, New Jersey, United States

Site Status

Research Site

Livingston, New Jersey, United States

Site Status

Research Site

Moorestown, New Jersey, United States

Site Status

Research Site

Neptune City, New Jersey, United States

Site Status

Research Site

North Plainfield, New Jersey, United States

Site Status

Research Site

Albany, New York, United States

Site Status

Research Site

Binghamton, New York, United States

Site Status

Research Site

Forest Hills, New York, United States

Site Status

Research Site

Lawrence, New York, United States

Site Status

Research Site

New York, New York, United States

Site Status

Research Site

Riverhead, New York, United States

Site Status

Research Site

Rochester, New York, United States

Site Status

Research Site

Staten Island, New York, United States

Site Status

Research Site

Utica, New York, United States

Site Status

Research Site

Greensboro, North Carolina, United States

Site Status

Research Site

Morehead City, North Carolina, United States

Site Status

Research Site

Raleigh, North Carolina, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Columbus, Ohio, United States

Site Status

Research Site

Mentor, Ohio, United States

Site Status

Research Site

Toledo, Ohio, United States

Site Status

Research Site

Portland, Oregon, United States

Site Status

Research Site

Salem, Oregon, United States

Site Status

Research Site

Bridgeville, Pennsylvania, United States

Site Status

Research Site

Carlisle, Pennsylvania, United States

Site Status

Research Site

Erie, Pennsylvania, United States

Site Status

Research Site

Sewickley, Pennsylvania, United States

Site Status

Research Site

Columbia, South Carolina, United States

Site Status

Research Site

Orangeburg, South Carolina, United States

Site Status

Research Site

Sumter, South Carolina, United States

Site Status

Research Site

Chattanooga, Tennessee, United States

Site Status

Research Site

Hendersonville, Tennessee, United States

Site Status

Research Site

Hixon, Tennessee, United States

Site Status

Research Site

Memphis, Tennessee, United States

Site Status

Research Site

Nashville, Tennessee, United States

Site Status

Research Site

Austin, Texas, United States

Site Status

Research Site

Beaumont, Texas, United States

Site Status

Research Site

Houston, Texas, United States

Site Status

Research Site

San Antonio, Texas, United States

Site Status

Research Site

Provo, Utah, United States

Site Status

Research Site

Salt Lake City, Utah, United States

Site Status

Research Site

McLean, Virginia, United States

Site Status

Research Site

Norton, Virginia, United States

Site Status

Research Site

Puyallup, Washington, United States

Site Status

Research Site

Seattle, Washington, United States

Site Status

Research Site

Spokane, Washington, United States

Site Status

Research Site

Tacoma, Washington, United States

Site Status

Research Site

Walla Walla, Washington, United States

Site Status

Research Site

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Pencek R, Roddy T, Peters Y, De Young MB, Herrmann K, Meller L, Nguyen H, Chen S, Lutz K. Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study. Diabetes Obes Metab. 2010 Jun;12(6):548-51. doi: 10.1111/j.1463-1326.2010.01201.x.

Reference Type DERIVED
PMID: 20518811 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

137-161

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

20 Week Bridging Study in Type II DM
NCT00563225 COMPLETED PHASE3